References
- Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30(02):93–98.
- Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340(jan21 1):b5569.
- Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–66.
- Ruano-Ravina A, Pérez-Ríos M, Casàn-Clará P, et al. Low-dose CT for lung cancer screening. Lancet Oncol. 2018;19(3):e131–2.
- Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
- de Koning HJ, van der Aalst CM, de Jong PA, et al., Reduced lung-cancer mortality with volume CT SCREENING IN A RANDOMIZED TRIAL. N Engl J Med. 2020;382(6): 503–513.
- Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ Health Perspect. 1995;103(Suppl):131–142.
- Pérez-Ortuño R, Martínez-Sánchez JM, Fu M, et al. Assessment of tobacco specific nitrosamines (TSNAs) in oral fluid as biomarkers of cancer risk: a population-based study. Environ Res. 2016;151:635–641.
- Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988;9(6):875–884.
- Hecht SS, Stepanov I, Carmella SG. Exposure and metabolic activation biomarkers of carcinogenic tobacco-specific nitrosamines. Acc Chem Res. 2016;49(1):106–114.
- Yuan J-M, Butler LM, Stepanov I, et al., Urinary tobacco smoke-constituent biomarkers for assessing risk of lung cancer. Cancer Res. 2014;74(2): 401–411.
- Park EY, Lim MK, Park E, et al. Relationship between urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and lung cancer risk in the general population: a community-based prospective cohort study. Frontiers in Oncology. 2021;11:493.
- Thomas CE, Wang R, Adams-Haduch J, et al., Urinary cotinine is as good a biomarker as serum cotinine for cigarette smoking exposure and lung cancer risk prediction. Cancer Epidemiol Biomarkers Prev. 2020;29(1): 127–132.
- Fu M, Fernandez E, Martínez-Sánchez JM, et al. Salivary cotinine concentrations in daily smokers in Barcelona, Spain: a cross-sectional study. BMC Public Health. 2009;9(1):320.
- Benowitz NL, Bernert JT, Foulds J, et al. Biochemical verification of tobacco use and abstinence: 2019 update. Nicotine Tob Res. 2020;22(7):1086–1097.
- Kaaks R, Hüsing A, Fortner RT. Selecting high-risk individuals for lung cancer screening; the use of risk prediction models vs. simplified eligibility criteria. Ann Transl Med. 2017;5(20):406.
- Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–736.
- Volk RJ, Mendoza TR, Hoover DS, et al. Reliability of self-reported smoking history and its implications for lung cancer screening. Prev Med Reports. 2020;17:101037.